Wednesday, March 13, 2024 7:31:15 PM
Zacks Equity Research
Wed, March 13, 2024
EXCERPTS:
Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors
The company's EPS is expected to grow 15% this year, crushing the industry average, which calls for EPS growth of 14.7%.
Right now, year-over-year cash flow growth for Collegium Pharmaceutical is 27.9%, which is higher than many of its peers. In fact, the rate compares to the industry average of 2.4%.
There have been upward revisions in current-year earnings estimates for Collegium Pharmaceutical. The Zacks Consensus Estimate for the current year has surged 5.2% over the past month.
Bottom Line
While the overall earnings estimate revisions have made Collegium Pharmaceutical a Zacks Rank #1 stock, it has earned itself a Growth Score of A ....
READ MORE:
https://finance.yahoo.com/news/3-reasons-why-collegium-pharmaceutical-164505922.html
Recent COLL News
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:26:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 10:24:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:39:36 PM
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 02/22/2024 09:09:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:03:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:15:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:13:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:04:28 PM
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:19:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 09:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 01:03:11 PM
- Collegium Provides 2024 Financial Guidance • GlobeNewswire Inc. • 01/03/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:36:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/21/2023 09:15:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 10:51:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/20/2023 09:28:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM